Related Experiment Video
Updated: Jan 13, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
Published on: May 16, 2025
Scarring Alopecia in Localized Dystrophic Epidermolysis Bullosa: A Case Report and a Scoping Review
Pratiksha Patra1, Sairekha Ravichandran2, Nishit Patel2
1Internal Medicine, University of South Florida, Tampa, USA.
Abstract:
Alopecia is a recognized complication of the epidermolysis bullosa (EB) group of blistering diseases, with diffuse and scarring alopecia seen in severe generalized EB. However, there is a dearth of literature characterizing alopecia in localized EB, with few reports of scarring and non-scarring alopecia in dystrophic EB (DEB). In this report, we present a case of a 58-year-old female with an eight-year history of pretibial DEB and a documented heterozygous COL7A1 mutation, who presented to the dermatology clinic with improving skin fragility after five months of topical beremagene geperpavec therapy, now noting gradual hair thinning on the vertex scalp over one year. Clinical examination revealed decreased hair density on the vertex and frontal scalp, with scattered sclerotic papules, without significant perifollicular scale or erythema. Two punch biopsies were obtained for histologic vertical and horizontal sections, revealing superficial and mid-dermal fibrosis encircling hair follicles at the infundibulum and isthmus, numerous fibrous stelae, a superficial perifollicular lymphocytic infiltrate with scattered follicular dyskeratotic keratinocytes, and preservation of sebaceous glands. Together, these findings were consistent with scarring alopecia with shared features of DEB and lichen planopilaris (LPP). We highlight the importance of recognizing scarring alopecia as a complication of DEB, with discernment for concomitant inflammatory etiologies that may co-occur, especially in a patient with a COL7A1 mutation.
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

